Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ascletis Enrolls 120 Patients for Phase III Trial of Glioblastoma Candidate

publication date: Sep 26, 2023

Hangzhou Ascletis Pharma has enrolled the first 120 patients in the China Phase III trial of ASC40 combined with bevacizumab to treat recurrent glioblastoma. ASC40 is an oral, selective small molecule inhibitor of fatty acid synthase, an enzyme that regulates de novo lipogenesis. ASC40 is expected to decrease energy supply and disturb the membrane phospholipid composition of tumor cells. In 2019, Ascletis acquired China rights to ASC40 from San Francisco's 3-V Biosciences for NASH. In a Phase II trial, the combination produced an overall response rate of 65% with a 20% complete response rate in patients with rGBM. More details....

Stock Symbol: (HK: 1672)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here